Should I Buy NAMS? NAMS 2026 Analysis

Should You Buy NewAmsterdam Pharma Company NV (NAMS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

31.120

1 Day change

-1.02%

52 Week Range

42.000

Analysis Updated At

2026/01/30

Not a good buy right now for an impatient buyer. The setup is still technically weak (bearish momentum and price below pivot), and pattern-based probabilities skew to further near-term downside. I would not chase pre-market at ~31.44; only turns into a buy if it quickly reclaims ~32.58 (pivot) and holds above it intraday.

Technical Analysis

Trend/Momentum: Bearish-to-weak. MACD histogram is below zero (-0.0517) and expanding negatively, signaling deteriorating momentum. RSI(6) at ~33 is near oversold territory, which can support a bounce, but it’s not a confirmed reversal signal by itself. Key levels: Price ~31.44 is below the pivot (32.583), which keeps the bias bearish/defensive. Near support S1 ~30.757 (then S2 ~29.629). Resistance levels: R1 ~34.409, R2 ~35.537. Moving averages: Converging MAs suggest no strong trend strength; combined with negative MACD, this often precedes continued chop-to-down. Pattern-based forward odds: Similar candlestick-pattern analysis shows a skew negative (40% chance to -12.77% next day; -6.02% next week; -17.29% next month), reinforcing that this is not an attractive immediate entry. Intellectia Proprietary Trading Signals - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock today.

Options Data

Bearish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment read: Open-interest put/call ratio at 1.65 is put-heavy, typically reflecting defensive positioning or bearish sentiment. Daily volume is extremely light (28 calls, 0 puts), so the volume put/call reads as 0.0 mainly because there were no puts traded that day—not necessarily bullish conviction. IV (30d) ~78.44 vs HV ~68.8 implies options are pricing elevated uncertainty, consistent with a biotech risk profile.

Technical Summary

Sell

Buy

Positive Catalysts

can trigger a reflex rally if buyers defend support.

Neutral/Negative Catalysts

Options positioning: Put-heavy open interest (PCR 1.
suggests cautious-to-bearish positioning.

Financial Performance

Latest quarter: 2025/Q3. Revenue fell sharply to ~$0.348M (-98.80% YoY), indicating minimal operating revenue base. Losses improved: Net income was -$72.005M (up 332.54% YoY) and EPS -0.61 (up 238.89% YoY), suggesting the loss narrowed versus the prior year period, but the company remains firmly loss-making. Gross margin is reported at 100 (likely reflecting low/atypical revenue mix rather than scaled profitability). Overall: improving loss trajectory, but weak top-line.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Upward revision. On 2026-01-21, RBC Capital raised its price target to $47 from $44 and maintained Outperform. Wall Street pros view (from available data): Pro = constructive outlook implied by higher PT and Outperform. Con = despite positive rating, current tape is weak and near-term catalysts/news flow is absent, so the market may not reward the bull thesis immediately.

10 Analyst Rating

Wall Street analysts forecast NAMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NAMS is 48.63 USD with a low forecast of 37 USD and a high forecast of 60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

1 Hold

0 Sell

Strong Buy

Current: 31.440

Low

Averages

48.63

High

Current: 31.440

Low

Averages

48.63

High

RBC Capital

Outperform

upgrade

$44 -> $47

AI Analysis

2026-01-21

Reason

RBC Capital

Price Target

$44 -> $47

AI Analysis

2026-01-21

upgrade

Outperform

Reason

RBC Capital raised the firm's price target on NewAmsterdam Pharma to $47 from $44 and keeps an Outperform rating on the shares. The firm updated models for several biotech companies after meeting with managements.

H.C. Wainwright

Joseph Pantginis

initiated

$52

2025-10-20

Reason

H.C. Wainwright

Joseph Pantginis

Price Target

$52

2025-10-20

initiated

Reason

H.C. Wainwright analyst Joseph Pantginis assumed coverage of NewAmsterdam Pharma with a Buy rating and $52 price target. NewAmsterdam is a late clinical-stage biopharmaceutical company developing obicetrapib, a non-statin, next-generation cholesterol ester transfer protein small molecule inhibitor for low-density lipoprotein cholesterol reduction, the analyst tells investors in a research note. The firm says obicetrapib is :poised to burst into the lipid-lowering space."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NAMS

Unlock Now

NAMS Should I Buy

NAMS Should I Buy

Should You Buy NewAmsterdam Pharma Company NV (NAMS) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch